AMRI has signed an exclusive option to enter a license agreement with Bessor Pharma, LLC, a translational drug development company, for the development of ALB 109564(a), AMRI’s novel tubulin inhibitor compound in Phase I trials for the treatment of cancer. The option period is approximately eight months. AMRI will receive an undisclosed option fee and reimbursement for certain costs associated with the intellectual property related to ALB 109564(a). Bessor will conduct fund raising and coordina...